Wire · operational-macro
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The US FDA has granted accelerated approval to Nelkarmi (neladalkib) for adults with previously treated advanced ALK-positive non-small cell lung cancer, based on the ALKOVE-1 trial demonstrating meaningful and durable responses. Nelkarmi is designed to address treatment resistance and brain metastases with improved tolerability, marking GSK's second lung cancer drug approval this year.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your lung cancer drug portfolio just gained a new competitor that handles resistant and brain metastasis cases better. If you work on ALK-positive NSCLC treatments, prepare for tougher differentiation and faster patient access to advanced therapies.
◆ Coverage
2 sources · 17 Nov 2026
◆ Related on Wire
◆ Topics